It is known that 19-nor-deoxycorticosterone (19-nor-DOC) is a potent mineralocorticosteroid that is present in urine of rats and humans in a free, i.e., nonconjugated, form. In some forms of hypertension in rats, the levels of free 19-nor-DOC in urine are increased compared with those in urine of normotensive animals. Yet, despite the potential importance of this mineralocorticosteroid in the pathogenesis of certain forms of hypertension, little is known of its site of origin or metabolism. In the present investigation, we evaluated the metabolism of intravenously infused [3H]19-nor-DOC and the possibility that 19-nor-DOC was formed from plasma DOC. We found that the metabolism of [3H]19-nor-DOC infused intravenously in men and women was similar to that of DOC with important exceptions. 
Introduction
Recently, there has been considerable interest in the potential role of 19-nor-deoxycorticosterone (19-nor-DOC)' as a mineralocorticosteroid in physiologic and possibly pathophysiologic processes. It is known that 19-nor-DOC is a potent mineralocorticosteroid (1) (2) (3) (4) (5) (6) that is present in nonconjugated form in urine of rats undergoing adrenal regeneration (5) and in rats with spontaneous (7) hypertension as well as in urine of normotensive animals. The levels of 19-nor-DOC in urine of these hypertensive rats appear to be greater than those in normotensive rats. From these findings, the possibility was considered that 19-nor-DOC may be instrumental in the pathogenesis of certain forms of hypertension. Recently, it also was demonstrated that free 19-nor-DOC is present in human urine (8) and that the levels of this nonconjugated steroid in urine increase after ACTH treatment (8) (9) (10) . In spite of these provocative findings, however, the tissue site(s) of biosynthesis of 19-nor-DOC is unknown and the metabolic fate of this mineralocorticosteroid is not defined. For example, it was not possible to demonstrate the biosynthesis of 19-nor-DOC in rat adrenal tissue in vitro (1 1, 12) .
Recently, we found that in the human, DOC is formed in extraadrenal sites from plasma progesterone (13) (14) (15) . Some extraadrenal tissues of DOC formation, e.g., kidney and aorta, are believed to be target tissues of DOC action (16) (17) (18) (19) . It was of interest, therefore, to determine whether 19-nor-DOC is formed from circulating DOC and if this were the source of nonconjugated 19-nor-DOC that is present in human urine. For these reasons, the present study was undertaken to evaluate the metabolism of intravenously infused radiolabeled 19-nor-DOC and DOC in men and women.
Methods
Radiolabeled steroid preparation, purification, and administration. [l,2(N-3H]19-nor-DOC (50 Ci/mmol) was synthesized as described (12) and purified by high performance liquid chromatography (HPLC) and by gradient-elution column chromatography on celite-ethylene glycol (13) . ["4CIDOC (50 mCi/mmol), purchased from New England Nuclear (Boston, MA), was purified as described (13) . A mixture of a tracer dose that consisted of ['4C]DOC (-18 gCi) and [3H] 19-nor-DOC (-7 uCi) in 4.5 ml NaCl (0.15 M) and 0.5 ml ethanol was infused intravenously into two healthy, ambulatory men, ages 47 and 52, and into two presumably ovulatory women, ages 33 and 35; thereafter, urine was collected from each subject for 72 h. Nonradiolabeled 19-nor-DOC was prepared as described (5) and the authenticity of this compound was validated by use of gas chromatography-mass spectrometry.
Urine processing and metabolite purification. Free, i.e., nonconjugated, 19-nor-DOC in the urine of each test subject was quantified by radioimmunoassay as described (20) . To evaluate the metabolism of the injected radiolabeled steroids, one-half of the urine collected was extracted with ethyl acetate to remove nonconjugated steroids. The other one-half of the urine was mixed with acetic acid to adjust the pH to 5.0. Thereafter, the acidified urine was incubated with 3-glucuronidase for 48 h at 370C to effect hydrolysis of steroid glucuronosides. The fl-glucuronidase-treated urine was extracted with ethyl acetate. The aqueous residues were combined and treated by solvolysis (21) to effect hydrolysis of steroid sulfates. Aliquots of the residues obtained from each urine extract were assayed for radioactivity.
Radiolabeled steroids in these residues were isolated by successive chromatographic procedures that included, initially, gradient-elution column chromatography on celite-ethylene glycol (13 By gradient-elution column chromatography, we isolated five major peaks of carbon-14 radioactivity and six peaks that contained tritium radioactivity. In the case of the carbon-14 peaks, there were corresponding peaks of tritium that were slightly more polar than the carbon-14 counterpart (Fig. 1) . We find, as do others (5, 12, 23) , that in most chromatographic systems, 19-nor-DOC is slightly more polar than DOC.
Radiolabeled 19-nor-DOC was one of the major tritiumlabeled metabolites isolated after j3-glucuronidase treatment of urine. This steroid was purified to radiochemical homogeneity (Fig. 2) and, thereafter, the specific activity of this urinary metabolite was determined by assay of radioactivity and quantification of mass by ultraviolet absorption. Carbon-14-labeled DOC was not present in urine after f3-glucuronidase treatment. (4, 5, 7) . Yet, the origin of the 19-nor-DOC that is found in urine of rats and humans (5, 7-10, 24, 25) is unknown. Intuitively, one would expect that such a steroid would be secreted by the adrenal cortex or else would be formed in extraadrenal tissues from DOC. It has not been possible, however, to demonstrate the biosynthesis of 19-nor-DOC in adrenal tissue (11, 12) .
Heretofore, investigators have quantified the amount of 19-nor-DOC that was present as the free steroid in urine of experimental animals (5, 7, 24) and humans (8-10, 24, 25 From these several observations, we conclude that free 19- nor-DOC in urine is formed in kidney from a precursor other than DOC or else is formed in kidney or in urine nonenzymatically from a precursor such as the 19-carboxylic acid derivative of DOC, a compound that is known to be synthesized in rat adrenal tissue in vitro (12) and, possibly, in man. This obtains since if the 19-nor-DOC that is found in urine as the free steroid were formed in tissues other than kidney, the likely metabolic fate of such a steroid would be similar to that of intravenously infused [3H] 19-nor-DOC; if not, there seems no reasonable manner by which it could reach urine as free 19-nor-DOC. On the other hand, it also is apparent that there is, in vivo, production of 19-nor-DOC that is independent of that which is formed in kidney or urine and excreted as the Steroid 21-hydroxylase activity has been demonstrated in a number of extraglandular tissues in humans (cf. 26) and the 21 -hydroxylation of plasma progesterone is known to account, in large measure, for the striking increase in the rate of production of DOC in women during the midluteal phase of the ovarian cycle (14, 27) and during pregnancy (13, 15 (33) , and in spleen, extraadrenal steroid 21-hydroxylase activity is altered by immunologic challenges (34) . In consideration of the biological potency of several of the compounds involved, it seems reasonable to suspect that aberrations in one or more of these unusual metabolic processes could give rise to abnormalities that involve mineralocorticosteroid action. In this context, it is important to note that Shackleton (35) could find little or no tetrahydro-19-nor-DOC in urine of persons with 17a-hydroxylase deficiency. This finding, as he properly notes, also stands in evidence against the proposition that 1 9-nor-DOC is synthesized in the adrenal. Moreover, our findings also are supportive of the proposition that free urinary 19-nor-DOC is not formed from plasma DOC. Based on these findings, we postulate that the free 19- nor-DOC in urine is formed either in kidney or else nonenzymatically in kidney or in urine from 19-oic-DOC that can be synthesized in adrenal tissue (12) . In support of the latter possibility are the recent findings of Griffing et al. (36) that the levels of 19-nor-DOC in plasma and urine of a woman with 17a-hydroxylase deficiency are increased as are the plasma levels of a precursor (possibly 19-oic-DOC) that is converted to 19-nor-DOC by acidification of plasma. These investigators demonstrated that plasma levels of 19-nor-DOC and the precursor are decreased by treatment with dexamethasone and increased by treatment with ACTH (36) . In addition, Griffing et al. (37) obtained evidence that 19-nor-DOC production is not regulated by the renin-angiotensin system. Thus, there is considerable evidence in favor of the proposition that 19-nor-DOC in urine arises in kidney or in urine from a precursor that is secreted by the adrenal.
